0000950170-24-002745.txt : 20240108 0000950170-24-002745.hdr.sgml : 20240108 20240108091201 ACCESSION NUMBER: 0000950170-24-002745 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 24518623 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 8-K 1 cgem-20240108.htm 8-K 8-K
false000178997200017899722024-01-082024-01-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 08, 2024

 

 

CULLINAN ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39856

81-3879991

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Main Street

Suite 1350

 

Cambridge, Massachusetts

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 410-4650

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

CGEM

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

As of December 31, 2023, Cullinan Oncology, Inc.’s (the “Company’s”) unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan.

The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, investments, and interest receivable as of December 31, 2023 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2023. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it.

The information contained in this Current Report on Form 8-K under Item 2.02 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and will not be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless specifically identified as being incorporated therein by reference.

 

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this Current Report on Form 8-K that are not historical facts may be considered “forward-looking statements,” including statements regarding the Company’s preliminary estimates of cash, cash equivalents, investments, and interest receivable as of December 31, 2023. Forward-looking statements are typically, but not always, identified by the use of words such as “estimate,” “expect,” and other similar terminology. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause the Company's actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results, including the risks that the preliminary financial results reported herein reflect information available to the Company only at this time and may differ from actual results, including in connection with the Company’s completion of financial closing procedures, risks associated with market conditions, risks and uncertainties associated with the Company’s business and finances in general, as well as the risks detailed in the Company’s recent filings on Forms 10-K and 10-Q with SEC. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Current Report on Form 8-K. Any forward-looking statement included in this Current Report on Form 8-K speaks only as of the date on which it was made.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CULLINAN ONCOLOGY, INC.

 

 

 

 

Date:

January 8, 2024

By:

/s/ Jeffrey Trigilio

 

 

 

Jeffrey Trigilio
Chief Financial Officer

 

 EX-101.SCH 2 cgem-20240108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 cgem-20240108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 cgem-20240108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 08, 2024
Entity Registrant Name CULLINAN ONCOLOGY, INC.
Entity Central Index Key 0001789972
Entity Emerging Growth Company true
Entity File Number 001-39856
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-3879991
Entity Address, Address Line One One Main Street
Entity Address, Address Line Two Suite 1350
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 410-4650
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CGEM
Security Exchange Name NASDAQ
XML 6 cgem-20240108_htm.xml IDEA: XBRL DOCUMENT 0001789972 2024-01-08 2024-01-08 false 0001789972 8-K 2024-01-08 CULLINAN ONCOLOGY, INC. DE 001-39856 81-3879991 One Main Street Suite 1350 Cambridge MA 02142 617 410-4650 false false false false Common Stock, $0.0001 par value per share CGEM NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports cgem-20240108.htm cgem-20240108.xsd cgem-20240108_lab.xml cgem-20240108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cgem-20240108.htm": { "nsprefix": "cgem", "nsuri": "http://www.cullinanoncology.com/20240108", "dts": { "inline": { "local": [ "cgem-20240108.htm" ] }, "schema": { "local": [ "cgem-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cgem-20240108_lab.xml" ] }, "presentationLink": { "local": [ "cgem-20240108_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7d5d09b9-3e0a-4920-8e4a-3a498cb78d17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cgem-20240108.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5d09b9-3e0a-4920-8e4a-3a498cb78d17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cgem-20240108.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.cullinanoncology.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-002745-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-002745-xbrl.zip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end